Key result
Angiopoietin-2 levels were significantly higher in rheumatoid arthritis patients with metabolic syndrome (5.31 ng/ml) than in those without (4.93 ng/ml) and healthy controls (4.44 ng/ml) (p < 0.001).
Why the study?
Are Angiopoietin-2 levels elevated in rheumatoid arthritis patients with metabolic syndrome compared to those without?
Observational (n=100)
Are Angiopoietin-2 levels elevated in rheumatoid arthritis patients with metabolic syndrome compared to those without?
Absolute Event Rate: 5.31% vs 4.93%
p-value: p=<0.001
Angiopoietin-2 levels are elevated in rheumatoid arthritis patients with metabolic syndrome and correlate with disease activity, suggesting its potential utility as a biomarker for cardiovascular risk in this population.
Ang-2 elevation associates with MetS in RA; hypothesis-generating for CV biomarker role, needs prospective validation before clinical use.
The incidence of metabolic syndrome (MetS) increases in rheumatoid arthritis (RA) patients which increases the risk of cardiovascular disease (CVD). Angiopoietin-2 levels increase in RA and were reported to predict CVD. To assess the level of angiopoietin-2 in RA patients and study its relation to disease activity and its role in those with MetS. The study included 80 RA patients (67 females and 13 males) and 20 healthy age and sex matched controls. The patients were divided into Group 1 (n = 40) with MetS and Group 2 (n = 40) without. Data were collected throughout history, basic clinical examination and investigation. Disease activity score (DAS-28) was assessed in all patients. Enzyme linked immunosorbent assay was used for the estimation of angiopoietin-2. The age and disease duration of those with MetS (40.7 ± 7.23 years and 9.63 ± 6.73 years respectively) and those without (38.6 ± 9.2 and 8.65 ± 5.52 years respectively) were comparable (p = 0.26 and p = 0.48 respectively). The disease activity (DAS-28) was also similar in both groups (5.12 ± 0.77 and 5.01 ± 0.96 respectively; p = 0.56). There was a significant increase in the angiopoietin-2 levels in RA patients with MetS (5.31 ± 0.56 ng/ml) than those without (4.93 ± 0.44 ng/ml) (p < 0.001). The levels were significantly higher than those of the control (4.44 ± 0.29 ng/ml) (p < 0.001). The angiopoietin-2 level significantly correlated with the DAS-28 (r = 0.23, p = 0.045), systolic (r = 0.36, p = 0.001) and diastolic blood pressure (r = 0.35, p = 0.001), fasting blood sugar (r = 0.29, p = 0.009) and triglycerides (r = 0.24, p = 0.03). Angiopoietin-2 can be used as a biomarker of MetS and disease activity in RA patients. This could point to those RA patients at risk of developing CVDs.
No takes yet. Share an insight, caveat, or question.
Ghazaly et al. (2015) conducted an observational in Rheumatoid arthritis and metabolic syndrome (n=100). Metabolic syndrome vs. No metabolic syndrome and healthy controls was evaluated on Angiopoietin-2 levels (p=<0.001). Angiopoietin-2 levels were significantly higher in rheumatoid arthritis patients with metabolic syndrome (5.31 ng/ml) than in those without (4.93 ng/ml) and healthy controls (4.44 ng/ml) (p < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: